Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 253 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levodopa Clear all
Recruiting Phase 4 Interventional

Dopaminergic Therapy for Anhedonia - 2

NCT06075771
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

NCT02577523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

NCT00869791
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

NCT01171313
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 17, 2026, 4:03 PM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

NCT00203957
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial of Levodopa in Angelman Syndrome

NCT01281475
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Levodopa, Placebo Oral Capsule
Drug
Lead sponsor
Wen-Hann Tan
Other
Eligibility
4 Years to 12 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 17, 2026, 4:03 PM EDT
Terminated Phase 4 Interventional

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

NCT00477802
View directory record Official record
Conditions
Parkinson Disease
Interventions
Botulinum Toxin Type A, Placebo
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2009 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT04435431
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mesdopetam, Placebo
Drug
Lead sponsor
Integrative Research Laboratories AB
Industry
Eligibility
30 Years to 79 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • Long Beach, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 17, 2026, 4:03 PM EDT
Completed No phase listed Observational

Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations

NCT00302146
View directory record Official record
Conditions
Parkinson Disease, Gaucher Disease
Interventions
15-0 H20
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Study of LY300164 for the Treatment of Parkinson's Disease

NCT00004576
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
LY300164
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

NCT00134966
View directory record Official record
Conditions
Parkinson's Disease
Interventions
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Reseda, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

NCT01397422
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
Interventions
ADS-5102 (extended release amantadine HCl)
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Sun City, Arizona • Fountain Valley, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence

NCT00218075
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Levodopa, Carbidopa, Clinical Management, Relapse Prevention Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 17, 2026, 4:03 PM EDT
Completed No phase listed Observational

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

NCT05560009
View directory record Official record
Conditions
Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Interventions
Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 17, 2026, 4:03 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT07432958
View directory record Official record
Conditions
Parkinson Disease
Interventions
AP-472, Placebo
Drug · Other
Lead sponsor
Appello Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 17, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional Results available

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

NCT00664209
View directory record Official record
Conditions
Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
Interventions
clartihromycin, amoxicillin, and omeprazole, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Cognitive Remediation for Cocaine Dependence

NCT01393457
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 17, 2026, 4:03 PM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Deep Brain Stimulation of the Cuneiform Nucleus for Levodopa-resistant Freezing of Gait in Parkinson's Disease

NCT04218526
View directory record Official record
Conditions
Parkinson Disease
Interventions
Vercise DBS System
Device
Lead sponsor
Jonathan Jagid
Other
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 4:03 PM EDT